Anavex First-in-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease

Hoboken, NJ — April 20, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease. “We are pleased that the first volunteers have been dosed with the…

Anavex Appoints Dr. Christopher Shackleton as an Advisor

Hoboken, NJ — April 8, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced the appointment of Dr. Christopher Shackleton as an advisor to the Company. Dr. Shackleton is a prominent, uniquely qualified physician and surgeon, clinical investigator, information technologist, and corporate finance/healthcare solutions consultant.  He holds triple specialist credentials in medical and…

Anavex Screening Healthy Volunteers for Phase I, First-in-Human Clinical Study in Alzheimer’s disease

Hoboken, NJ — March 31, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease.  ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which…

Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease

ANAVEX 2-73 trial to be initiated immediately in Germany Hoboken, NJ — March 15, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL)  today announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM.  The Phase I trial…